ИММУНОТЕРАПИЯ ИНФЕКІІИОННО-ВОСПАЛИТЕЛЬНЬІХ ЗАБОЛЕВАНИЙ МОЧЕВЫВОДЯЩИХ ПУТЕЙ И ЕЕ ЭФФЕКТИВНОСТЬ

  • Авторы: Шевяков М.А.1
  • Учреждения:
    1. ГБОУ ВПО “Северо-Западный государственный медицинский университет им. И.И. Мечникова” Минздравсоцразвития России
  • Выпуск: № 2 (2013)
  • Страницы: 98-102
  • Раздел: Статьи
  • URL: https://journals.eco-vector.com/1728-2985/article/view/279749
  • ID: 279749

Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Полный текст

Доступ закрыт

Об авторах

М. А. Шевяков

ГБОУ ВПО “Северо-Западный государственный медицинский университет им. И.И. Мечникова” Минздравсоцразвития России

Email: shevyakov@inbox.ru
Кафедра клинической микологии, аллергологии и иммунологии д-р мед. наук, профессор кафедры Санкт-Петербург

Список литературы

  1. Кульчавеня Е.В. Трудности диагностики туберкулеза мочеполовой системы. Новосибирск, 2004.
  2. Рафальский В.В., Страчунский Л.С., Кречикова О.И. и др. Резистентность возбудителей амбулаторных инфекций мочевыводящих путей по данным многоцентровыіх микробиологических исследований UTIAP—I и UTIAP—II. Урология. 2004;2:14—17.
  3. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113(Suppl. 1A):5S—13S.
  4. Naber K.G., Schito G., Botto H. et al. Surveillance study in Europe and Brazil on clinical aspects and antimicrobial resistance epidemiology in females with cystitis (ARESC): implications for empiric therapy. Eur Urol. 2008;54:1164—1178.
  5. Hooton T.M., Scholes D., Hughes J.P. et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med. 1996;335:468—474.
  6. Wagenlehner F.M., Weidner W., Naber K.G. Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005;10:275—298.
  7. Grabe M., Bishop M.C., Bjerklund-Johansen T.E. et al. Guidelines on urological infections. European Association of Urology Web site.
  8. Raz R., Stamm W.E. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329:753—756.
  9. Raz R., Chazan B., Kennes Y. et al. Empiric use of trimethoprimsulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis. 2002;34:1165—1169.
  10. Albert X., Huertas I., Pereirô II. et al. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev 2004:CD001209.
  11. Reid G. Probiotic therapy and functional foods for prevention of urinary tract infections: state of the art and science. Curr Infect Dis Rep. 2000;2:518—522.
  12. Fünfstück R., Straube E., Schildbach O. et al. Prevention of reinfection by L-methionine in patients with recurrent urinary tract infection. Med Klin (Munich). 1997;92:574—581.
  13. Avorn J., Monane M., Gurwitz JH. et al. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. JAMA. 1994;271:751—754.
  14. Jepson R.G., Mihaljevic L., Craig J. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 2004:CD001321.
  15. Bessler W.G., Puce K., vor dem Esche U. et al. Immunomodulating effects of OM-89, a bacterial extract from Escherichia coli, in murine and human leukocytes. Arzneimittelforschung/Drug Research. In press.
  16. Schmidhammer S., Ramoner R., Höltl L. et al. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. Urology. 2002;60:521—526.
  17. Van Pham T., Kreis B., Corradin-Betz S. et al. Metabolic and functional stimulation of lymphocytes and macrophages by an Escherichia coli extract (OM-89): in vitro studies. J Biol Response Mod. 1990;9:231—240.
  18. Marchant A., Duchow J., Goldman M. Adhesion molecules in antibacterial defenses: effects of bacterial extracts. Respiration. 1992;59(Suppl. 3):24—27.
  19. Chiavaroli C., Moore A. An hypothesis to link the opposing immunological effects induced by the bacterial lysate OM-89 in urinary tract infection and rheumatoid arthritis. BioDrugs. 2006;20:141—149.
  20. Huber M., Krauter K., Winkelmann G. et al. Immunostimulation by bacterial components: II. Efficacy studies and meta-analysis of the bacterial extract OM-89. Int J Immunopharmacol. 2000; 22:1103—1111.
  21. Huber M., Baier W., Serr A. et al. Immunogenicity of an E. coli extract after oral or intraperitoneal administration: induction of antibodies against pathogenic bacterial strains. Int J Immunopharmacol. 2000;22:57—68.
  22. Lee S.J., Kim S.W., Cho Y.H. et al. Anti-inflammatory effect of an Escherichia coli extract in a mouse model of lipopolysaccharide-induced cystitis. World J Urol. 2006;24:33—38.
  23. Bauer H.W., Alloussi S., Egger G. et al. on behalf of Multicenter UTI Study Group. A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol. 2005;47:542—548.
  24. Hachen H.J. Oral immunotherapy in paraplegic patients with chronic urinary tract infections: a double-blind, placebo-controlled trial. J Urol. 1990;143:759—762.
  25. Lettgen B. Prevention of recurrent urinary tract infections in female children: OM-89 immunotherapy compared with nitrofurantoin prophylaxis in a randomized pilot study. Curr Ther Res. 1996;57:464—475.
  26. Naber K.G., Cho Y.H., Matsumoto T. et al. Immunoactive prophylaxis ofrecurrent urinary tract infections: a meta-analysis. Int J Antimicrob Agents. 2009;33:111—119.
  27. Magasi P., Pânovics J., Illés A. et al. Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial. Eur Urol. 1994;26:137—140.
  28. Baertschi R., Balmer J.A., Eduah S.B. et al. Bacterial extract for the prevention of recurrent urinary tract infections in pregnant women: a pilot study. Int J Immunother. 2003;19:25—31.
  29. Tammen H. Immunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. The German Urinary Tract Infection Study Group. Br J Urol. 1990;65:6—9.
  30. Pisani E., Palla R., Bono A.V. Double-blind randomised clinical study of OM-8930 vs placebo in patients suffering from recurrent urinary tract infections [quoted by Chiavaroli C, Moore A. An hypothesis to link the opposing immunological effects induced by the bacterial lysate OM-89 in urinary tract infection and rheumatoid arthritis. BioDrugs 2006; 20:141—9]. Geneva, Switzerland: OM PHARMA; 1992.
  31. Schulman C.C., Corbusier A., Michiels H. et al. Oral immunotherapy of recurrent urinary tract infections: a double-blind placebocontrolled multicenter study. J Urol. 1993;150:917—921.
  32. Zenewicz L.A. et al. Trends in Molecular Medicine 2009;5:199—207.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах